Cocrystal Pharma reported a Q2 2025 net loss of $2.1 million, an improvement from a $5.3 million loss in Q2 2024. This was driven by a significant reduction in research and development expenses. The company ended the quarter with $4.8 million in cash and 10.2 million shares outstanding, while continuing to advance its antiviral pipeline.

Cocrystal Pharma reported a reduced net loss and lower operating expenses in the first quarter of 2025 compared to the same period in the previous year. The company is advancing its antiviral product pipeline, particularly its norovirus candidate CDI-988, with plans for a human challenge study.

Cocrystal Pharma reported a net loss of $4.9 million, or $0.49 per share, for the third quarter of 2024. The company's cash balance was $13.0 million as of September 30, 2024, which is expected to fund planned development programs for the next 12 months. Topline results from two ongoing clinical studies are expected before year end and in late 2024 or early 2025.

Cocrystal Pharma reported a net loss of $5.3 million, or $0.54 per share, for the second quarter of 2024. The company's R&D expenses increased due to the advancement of CC-42344 and CDI-988 into clinical studies. They expect their cash to be sufficient to advance planned development programs through the coming 12 months.

Cocrystal Pharma reported a net loss of $4.0 million, or $0.39 per share, for the first quarter of 2024, compared to a net loss of $5.2 million, or $0.64 per share, for the first quarter of 2023. The company's cash balance was $21.8 million as of March 31, 2024, and anticipates significant milestones this year.

Cocrystal Pharma reported a net loss for 2023 of $18.0 million, or $1.87 per share, compared to a net loss of $38.8 million in 2022. The company's cash position was reported as $26.4 million as of December 31, 2023, and believes it is sufficient to fund current operations including planned clinical studies beyond the next 12 months.

Cocrystal Pharma reported a net loss of $4.2 million, or $0.41 per share, for the third quarter of 2023, compared to a net loss of $5.7 million, or $0.70 per share, for the third quarter of 2022. The company's cash position is believed to be sufficient to fund planned operations beyond the next 12 months.

Cocrystal Pharma reported a net loss of $4.2 million, or $0.41 per share, for the second quarter of 2023. The company's cash position is sufficient to fund planned operations for the next 12 months.

Cocrystal Pharma reported a net loss of $5.2 million, or $0.64 per share, for the first quarter of 2023, compared to a net loss of $4.2 million, or $0.52 per share, for the first quarter of 2022. The company's cash balance was $34.0 million as of March 31, 2023. They are advancing their antiviral pipeline, including COVID-19, influenza, and norovirus programs.

Cocrystal Pharma reported a net loss of $24.4 million, or $0.25 per share, for the second quarter of 2022, which included a non-cash impairment charge of $19.1 million. The company's cash balance was $51.0 million as of June 30, 2022, and they believe it is sufficient to fund planned operations into 2024.

Cocrystal Pharma reported a net loss of $4.2 million, or $0.04 per share, for the first quarter of 2022. The company's cash balance was $54.8 million as of March 31, 2022, which is expected to fund planned operations through 2023. The company is advancing its antiviral programs for influenza and COVID-19, with Phase 1 studies underway or planned.

Cocrystal Pharma reported no revenues for 2021 compared to $2.0 million in 2020 due to Merck assuming activities and expenses for the influenza A/B collaboration. R&D expenses increased to $8.8 million, and the net loss was $14.2 million, or $0.16 per share. The company's cash position remains strong with $58.7 million.

Cocrystal Pharma reported no revenues for Q3 2021 compared to $489,000 in Q3 2020. R&D expenses were $2.2 million, and G&A expenses were $1.8 million. The net loss for the quarter was $3.9 million, or $0.04 per share.